IMAGE ANALYSIS GROUP will be attending the World Medical Innovation Forum on September 22–23.
Public source
Publisher name
Public post
Excited to share that IMAGE ANALYSIS GROUP will be at the World Medical Innovation Forum on September 22–23! I'll be joining conversations with CEOs from leading pharma…
Company
IMAGE ANALYSIS GROUP
Imaging | Clinical Trials | Powered by DYNAMIKA™ | Fueled by Expertise
- Industry
- Biotechnology Research
- Location
- London, GB
- Company size
- 51–200 employees
About IMAGE ANALYSIS GROUP
Image Analysis Group (IAG) is a global imaging CRO and imaging core lab for biotech and pharma sponsors. IAG delivers end-to-end medical imaging services for clinical trials that use imaging to assess drug safety and efficacy, supporting Phase I to Phase IV studies in oncology, rheumatology, orthopedics, obesity, cardiology, hepatology, neurology, and rare disease. What is an imaging CRO? IAG designs and executes the imaging component of a clinical trial - from imaging endpoint strategy through to regulatory submission - using a centralized imaging core lab model. Imaging modalities supported: X-ray, DXA, CT, MRI, DCE-MRI, functional MRI, PET, PET/CT, PET/MR, SPECT, ultrasound, and cardiac safety imaging. Services: • Imaging endpoint strategy and protocol design - imaging biomarkers and scoring systems including RECIST, iRECIST, mRECIST, RANO, Sharp, van der Heijde, RAMRIS, OARSI, Kellgren–Lawrence, and PDFF; feasibility, sample size, and regulatory alignment with FDA, EMA, MHRA, and PMDA • Imaging Charter, Imaging Manual, Imaging Review Charter, and SOPs aligned to ICH-GCP and 21 CFR Part 11 • Site qualification, technologist training, positioning kits, and 24/5 multilingual site support • Secure DICOM image collection, transfer, de-identification, technical and protocol QC, and audit trail • Centralized independent radiological review by board-certified radiologists, with chronological, paired, and randomized reading paradigms and third-reader adjudication • Quantitative imaging and AI-based analysis via DYNAMIKA™, IAG's proprietary platform for automated quantification of synovitis, bone marrow edema, erosions, tumor volumetrics, perfusion, diffusion, and liver fat fraction • Regulatory support for IND, IMPD, NDA, BLA, and MAA submissions and FDA Type B and C meetings ISO 27001, ISO 9001, GDPR, HIPAA, and 21 CFR Part 11 compliant. Global operations across the UK, EU, US, and APAC. Contact IAG to scope your next imaging trial: contact@ia-grp.com
See moreLatest activity
Latest activity from IMAGE ANALYSIS GROUP
6 signals
Presence & Recognition
IMAGE ANALYSIS GROUP is attending the H.C. Wainwright & Co., LLC 28th Annual Global Investment Conference in New York, USA on September 14–15, 2026, featuring Dr. Olga Kubassova and Mike Fisher PhD FRSC.
Presence & Recognition
IMAGE ANALYSIS GROUP is attending the World Medical Innovation Forum on the 22nd to 23rd of September in Boston.
Presence & Recognition
IMAGE ANALYSIS GROUP celebrated 19 years of operations, focused on bringing meaningful technology into drug development.
Discover more
Similar signals
Similar public activity from other companies.
Presence & Recognition
PhaseV
PhaseV is attending the World Medical Innovation Forum in Boston from September 22 to 23 to discuss clinical development and AI applications.
Presence & Recognition
Perceptive Inc.
Perceptive Inc. is presenting new research on an imaging-enabled orthotopic PDAC model combining patient-derived 3D spheroids with longitudinal MRI and ultrasound at the WMIC 2026 opening poster session.
Presence & Recognition
BIOEMTECH
BIOEMTECH is attending the World Molecular Imaging Society (WMIS) congress in Salt Lake City, USA, at Booth 503, alongside partners at LabLogic Systems.
Presence & Recognition
MILabs
MILabs is attending the Wmic2026 conference in Salt Lake City at Booth 103 to connect with colleagues, collaborators, and friends from the molecular imaging community.
Presence & Recognition
VisiCELL Medical Inc.